MARKET

RGNX

RGNX

Regenxbio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

33.97
+0.95
+2.88%
Opening 14:51 08/10 EDT
OPEN
32.79
PREV CLOSE
33.02
HIGH
34.33
LOW
32.62
VOLUME
157.28K
TURNOVER
--
52 WEEK HIGH
54.97
52 WEEK LOW
20.03
MARKET CAP
1.27B
P/E (TTM)
-12.2401
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average RGNX stock price target is 63.38 with a high estimate of 100.00 and a low estimate of 36.00.

EPS

RGNX News

More
Regenxbio EPS misses by $0.06, misses on revenue
REGENXBIO (NASDAQ:RGNX): Q2 GAAP EPS of -$0.91 misses by $0.06. Revenue of $16.57M (+110.3% Y/Y) misses by $5.66M. Cash, cash equivalents and marketable se
seekingalpha · 3d ago
Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates
Regenxbio (RGNX) delivered earnings and revenue surprises of -2.25% and -14.56%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 3d ago
REGENXBIO Reports Second Quarter 2020 Financial Results and Operational Highlights
REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced financial results for the quarter ended Jun
PR Newswire · 3d ago
Regenxbio announces positive one-year data on wet AMD gene therapy
REGENXBIO (NASDAQ:RGNX) announces positive one-year data from cohorts 4 & 5 of its Phase 1/2a clinical trial evaluating gene therapy RGX-314 in patients wi
seekingalpha · 6d ago
Did Hedge Funds Make The Right Call On Regenxbio Inc (RGNX) ?
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which
Insider Monkey · 6d ago
REGENXBIO Announces Additional Positive Interim Phase 1/2a Trial Update And Program Updates For RGX-314 For Treatment Of Wet AMD
Company on track to initiate RGX-314 subretinal delivery pivotal program by the end of 2020 RGX-314 was generally well-tolerated in 42 patients at all dose levels in Phase I/IIa trial Positive interim update from
Benzinga · 6d ago
REGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update and Program Updates for RGX-314 for the Treatment of Wet AMD
Company on track to initiate RGX-314 subretinal delivery pivotal program by the end of 2020
PR Newswire · 6d ago
REGENXBIO To Host Conference Call on August 6 to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights
REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Thur
PR Newswire · 07/30 20:05

Industry

Biotechnology & Medical Research
-0.07%
Pharmaceuticals & Medical Research
-0.04%

Hot Stocks

Symbol
Price
%Change

About RGNX

REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet age-related macular degeneration (wet AMD). Its product candidate, RGX-501, is meant for the treatment of homozygous familial hypercholesterolemia (HoFH). It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II), respectively. Its product candidates utilize viral vectors from its gene delivery platform, NAV Technology Platform.
More

Webull offers kinds of Regenxbio Inc stock information, including NASDAQ:RGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGNX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RGNX stock methods without spending real money on the virtual paper trading platform.